Sun Pharmaceutical Industries to Host Investor Call on Organon & Co. Acquisition
Sun Pharmaceutical Industries Limited announced that it would host an Investor Call to discuss the acquisition of Organon & Co. The event is scheduled for April 27, 2026.The Company’s senior management will participate in the call to provide updates regarding the announced asset. The meeting is scheduled for 08:00 am IST on April 27, 2026, and will be held via a Video Conference (VC).
Details for participating in the Investor Call are as follows:
| Date | 27 April 2026 |
|---|---|
| Time | 08:00 am IST |
| Mode | Video Conference (VC) |
| Meeting Link | https://us06web.zoom.us/webinar/register/WN_uNCmyjStTBavY5oLF7IbpQ#/registration |
About Sun Pharmaceutical Industries Limited
Sun Pharma is recognized as the world's leading specialty generics company, maintaining a presence across Innovative Medicines, Generics, and Consumer Healthcare products. It operates as India's largest pharmaceutical company and is a leading generic company in the US as well as Global Emerging Markets.The company's high-growth Global Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology, accounting for approximately 20% of company sales. Sun's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents, and the firm operates with a multi-cultural workforce drawn from over 50 nations.
SUNPHARMA Stock Price Movement
On Friday, Sun Pharmaceutical Industries Limited shares slipped by 3.67% to close at ₹1620.4. The stock traded on a significant volume of 9.61 million shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.